Breakthrough in Intrahepatic Cholangiocarcinoma Treatment: New Combination Therapies Show Promise

What Makes Intrahepatic Cholangiocarcinoma Such a Daunting Challenge?

Intrahepatic cholangiocarcinoma (ICC) remains one of the most challenging malignancies in oncology, with rising global incidence rates particularly in Southeast Asia. As the second most common form of liver cancer, ICC presents significant therapeutic challenges due to its late-stage diagnosis and limited treatment options. Most patients are diagnosed at advanced stages when surgical intervention is no longer viable, resulting in dismal survival rates of just 4-6 months without treatment. Recent clinical advances have explored various combination therapies to improve outcomes in this difficult-to-treat population, but the optimal treatment strategy remains unclear.

Could Innovative Combination Therapies Transform Treatment Approaches?

A recent phase 2 clinical trial conducted at Zhongshan Hospital of Fudan University has provided new insights into potential first-line treatment options for patients with advanced ICC. This single-center, randomized, open-label study compared two promising combination regimens: lenvatinib plus the anti-PD1 antibody toripalimab (Arm A) versus lenvatinib plus gemcitabine-oxaliplatin chemotherapy (GEMOX) (Arm B). The trial enrolled 61 participants between March and October 2020, with 31 patients randomized to Arm A and 30 to Arm B. This investigation follows a previous study at the same center that showed promising results with a triple-therapy approach combining toripalimab, lenvatinib, and GEMOX, raising questions about whether simplifying the regimen could maintain efficacy while reducing toxicity.

The study population included adults aged 18-75 with histopathologically confirmed ICC, measurable disease by RECIST 1.1 criteria, and good performance status (ECOG 0-1). Notably, a high proportion of patients in both arms (approximately 77%) were positive for hepatitis B markers, reflecting the epidemiological landscape in the region. Most patients (about 80% in Arm A and 77% in Arm B) had stage IV disease, underscoring the advanced nature of the study population. Treatment in Arm A consisted of toripalimab 240 mg intravenously every three weeks plus daily oral lenvatinib (dosed by weight: 8 mg for patients under 60 kg, 12 mg for those 60 kg or above). Arm B patients received identical lenvatinib dosing plus GEMOX chemotherapy (oxaliplatin 85 mg/m² on day 1 and gemcitabine 1 g/m² on days 1 and 8) every three weeks for 6-8 cycles.

How Do the New Regimens Perform in Terms of Efficacy and Safety?

With a median follow-up of 18.2 months, both treatment approaches demonstrated encouraging clinical activity. In Arm A, the objective response rate (ORR) was 32.3% (all partial responses), with a disease control rate (DCR) of 74.2%. The median overall survival (OS) reached 20.3 months, with one-year and two-year survival rates of 58.1% and 38.7%, respectively. Median progression-free survival (PFS) was 8.9 months. Notably, three patients achieved sufficient tumor reduction to undergo surgical resection after treatment. In Arm B, the ORR was slightly higher at 40.0%, with a DCR of 86.7%. Median OS was 15.5 months, with one-year and two-year survival rates of 62.3% and 33.4%. The median PFS was comparable to Arm A at 8.0 months. These results represent a substantial improvement over historical outcomes for advanced ICC, where median survival typically ranges from 11-12 months with standard chemotherapy.

The safety profiles of both regimens proved manageable, though with distinct differences between the two approaches. In Arm A, the most common adverse events included fatigue (71%), paresthesia (45%), gingivitis (45%), and immune-related events such as hypothyroidism (71%). No grade 4 adverse events occurred in this group. Arm B patients experienced similar rates of fatigue (63%) and paresthesia (40%), but had higher incidences of chemotherapy-related toxicities including nausea (50%), vomiting (46.7%), and hematological adverse events. Two patients in Arm B experienced grade 4 thrombocytopenia. Treatment modifications were required in 8 patients in Arm A and 9 patients in Arm B due to adverse events, with the relative dose intensity reduced to 50% in these cases. Importantly, no treatment-related deaths occurred in either arm, suggesting both approaches have acceptable safety profiles for this patient population.

Can Biomarkers Guide Patient Selection?

An intriguing aspect of this study was the exploration of potential biomarkers of response. In Arm A, researchers found that baseline neutrophil percentage and neutrophil count were significantly higher in patients who achieved objective responses compared to non-responders. This finding suggests that baseline immune parameters might help identify patients most likely to benefit from immunotherapy-containing regimens. Additionally, responders in Arm A showed significant reductions in monocyte percentage, monocyte count, and IL-8 levels following treatment, indicating immunotherapy might attenuate pro-inflammatory activity in the tumor microenvironment. Conversely, in Arm B, responders showed decreases in neutrophil and basophil proportions with increased monocyte proportions after treatment, suggesting different immune modulation mechanisms between the two approaches.

The study also evaluated the relationship between peripheral blood markers and treatment response through univariate logistic regression analysis. In Arm A, baseline neutrophil percentage (OR=1.117, 95% CI: 1.002–1.244, P=0.045) and neutrophil count (OR=1.453, 95% CI: 1.015–2.080, P=0.041) were significantly associated with response to treatment. No statistically significant associations were identified between baseline peripheral blood markers and treatment response in Arm B. The contrasting trends in monocyte levels after treatment between the two arms—decreasing in Arm A but increasing in Arm B—highlight potentially different immune mechanisms at play, warranting further investigation through mechanistic studies.

What Are the Implications for Future Clinical Practice?

Notably, this trial builds upon recent advances in ICC treatment demonstrated in other landmark studies. The TOPAZ-1 trial showed that adding durvalumab to gemcitabine plus cisplatin improved two-year overall survival to 23.6% compared to 11.5% with chemotherapy alone. Similarly, the KEYNOTE-966 trial demonstrated that pembrolizumab combined with gemcitabine and cisplatin extended median OS to 12.7 months versus 10.9 months with chemotherapy alone. The current study's results compare favorably with these benchmarks, suggesting that both lenvatinib-based combinations deserve further investigation as potential first-line options.

While these results are promising, several limitations must be acknowledged. The single-center design and relatively small sample size limit the generalizability of the findings. Additionally, the study population was younger and healthier than typical ICC patients encountered in clinical practice, which may have favorably influenced outcomes. The non-comparative nature of the trial design also prevents direct statistical comparison between the two treatment approaches. Nevertheless, this study provides valuable insights into potential first-line treatment options for advanced ICC and suggests several directions for future research.

The findings from this trial raise important questions for the field. Could baseline immune parameters, such as neutrophil counts, serve as predictive biomarkers for selecting patients most likely to benefit from immunotherapy-based approaches? How might the differing toxicity profiles of these regimens influence treatment selection in real-world clinical settings? What molecular or immunological mechanisms underlie the observed differences in peripheral blood marker changes between the two treatment approaches? Future larger-scale, multi-center trials will be needed to validate these findings and further refine treatment strategies for patients with advanced ICC.

In conclusion, this phase 2 trial demonstrates that both lenvatinib plus toripalimab and lenvatinib plus GEMOX show promising efficacy with manageable safety profiles as first-line treatments for advanced intrahepatic cholangiocarcinoma. While neither dual-therapy approach fully matched the efficacy of the previously reported triple combination, both regimens offer potential alternatives with favorable benefit-risk profiles. These findings represent an important step forward in the evolving treatment landscape for this challenging malignancy and warrant further investigation in larger confirmatory trials.

Summary

This comprehensive clinical trial investigated two combination therapies for advanced intrahepatic cholangiocarcinoma (ICC): lenvatinib plus toripalimab (Arm A) and lenvatinib plus GEMOX chemotherapy (Arm B). The study involved 61 patients and showed promising results for both approaches. Arm A achieved a 32.3% objective response rate with median overall survival of 20.3 months, while Arm B showed a 40% response rate with 15.5 months median survival. Both regimens demonstrated manageable safety profiles, though with different adverse event patterns. The study also revealed potential biomarkers for treatment response, particularly in relation to neutrophil counts and immune parameters. These findings represent a significant advancement in ICC treatment, though larger multi-center trials are needed for validation.